Accueil・Liste d'Actions・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Fermé

SecteurSoins de santé

115.09 -1.5

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

114

Max

119.65

Chiffres clés
By Trading Economics
Revenu	-49M -105M
Ventes	11M 71M
BPA	-0.73
Marge bénéficiaire	-147.27
Employés	414
EBITDA	5.9M -44M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+21.15% upside

Dividendes
By Acuity
Prochains Résultats	3 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	901M 8B
Ouverture précédente	116.59
Clôture précédente	115.09

Sentiment de l'Actualité

By Acuity

50%

152 / 340 Classement par Healthcare

Rhythm Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 août 2026, 19:46 UTC

Event

Rhythm Pharmaceuticals received expanded marketing authorization for IMCIVREE in the UK. Shares are trading higher since Tuesday's close, near the upper end of their one-month range.

11 août 2026, 19:36 UTC

Social Media

News

Event

Rhythm Pharmaceuticals received expanded UK approval for IMCIVREE to treat obesity, yet shares are declining amid broader market sentiment concerns.

10 août 2026, 19:31 UTC

Rhythm Pharmaceuticals Inc shares are lower today, retracing gains after an early drop. The stock is experiencing unusually high trading volume.

7 août 2026, 20:06 UTC

News

RYTM higher after JPMorgan raised price target to $146.00.

6 août 2026, 21:05 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reaching a high and remaining above the 20-day moving average. No specific news was identified.

5 août 2026, 20:02 UTC

Event

News

Rhythm Pharmaceuticals shares rise as Citigroup, RBC, and Citizens raise price targets to $143, $155, and $160, respectively, reflecting growing confidence in the company.

4 août 2026, 20:13 UTC

News

Rhythm Pharmaceuticals shares are trading higher in after-market hours following CEO and CFO participation in upcoming investor conferences, enhancing visibility among stakeholders.

3 août 2026, 19:51 UTC

Rhythm Pharmaceuticals Inc shares are higher today amid unusually high trading volume, continuing the upward trend since Friday's close. No specific news was identified.

31 juil. 2026, 22:56 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, despite earlier fluctuations and no specific news identified to explain the movement.

30 juil. 2026, 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, continuing a downward trend since Wednesday. No specific news has been identified to explain the decline.

29 juil. 2026, 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, influenced by rising oil prices amid escalating Middle East tensions, though no specific company news was identified.

28 juil. 2026, 19:11 UTC

Rhythm Pharmaceuticals Inc. shares are higher today, supported by strong trading volume and positive momentum in the biotechnology sector. No specific news was identified.

27 juil. 2026, 19:33 UTC

News

RYTM trades higher after JPMorgan's Overweight rating and $145 target.

24 juil. 2026, 21:01 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reflecting a positive shift since Friday's close despite broader market challenges.

21 juil. 2026, 14:36 UTC

News

Rhythm Pharmaceuticals will report second-quarter 2026 results on August 4, contributing to higher shares amid positive market sentiment and gains in the Nasdaq 100 Index.

20 juil. 2026, 20:51 UTC

Rhythm Pharmaceuticals Inc is lower in after-market trading, down significantly from Monday's close and below its 20-day moving average. No specific news was identified.

Comparaison

Variation de prix

Rhythm Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

21.15% hausse

Prévisions sur 12 Mois

Moyen 142.47 USD 21.15%

Haut 160 USD

Bas 105 USD

Basé sur 15 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

15 ratings

Achat

Maintien

Vente

Basé sur 15 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

152 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.